Printer Friendly

IMMUNOMEDICS REPORTS LYMPHOMA IMAGING AND THERAPY TEST RESULTS POSITIVE PHASE II STAGING AND THERAPY FINDINGS

 MORRIS PLAINS, N.J., April 19 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) presented a summary of Phase II results with its ImmuRAID(TM)-LL2 product for imaging non-Hodgkin's lymphomas at the annual meeting of the German Society for Nuclear Medicine. In over 80 percent of patients studied at three medical centers in Chicago, Ill., Baton Rouge, La., and Newark, N.J., ImmuRAID-LL2 was successful in tracking the sites of lymphomas, frequently revealing tumors missed by conventional imaging tests. These results were reviewed by Immunomedics' chairman, Dr. David M. Goldenberg, at the conference in Cologne, Germany.
 According to Dr. Goldenberg, "Our results with the new lymphoma imaging agent suggest that this test alone can compete well with a battery of diagnostic tests that include X-rays, CT scans, bone scans, and other nuclear imaging agents. We believe ImmuRAID-LL2 will be particularly appropriate for diagnosing low-grade lymphomas, which are especially difficult to manage."
 Mr. David W. Ortlieb, Immunomedics' president and chief executive officer added that "these results have led us to plan Phase III trials with this agent, which holds Orphan Drug status from the U.S. Food and Drug Administration."
 Non-Hodgkin's lymphomas afflict over 36,000 Americans annually, and this incidence is increasing due to AIDS. Immunomedics scientists believe that ImmuRAID-LL2's ability to reveal lymphoma tumors in AIDS patients will improve their prospects for therapy. ImmuRAID-LL2 comprises a mouse antibody fragment labeled with technetium-99m, a readily available isotope used at most nuclear medicine departments. According to Dr. Goldenberg, "the use of a small antibody fragment with this preferred isotope is fundamental to all of our imaging agents, making them rapid, simple, and relatively safe agents, based upon our clinical results to date."
 Dr. Goldenberg also discussed the imaging agent's therapeutic counterpart, ImmuRAIT(TM)-LL2, which is the same antibody linked with a therapeutic isotope. According to Dr. Goldenberg, "In Phase I/II trials, a small series of lymphoma patients who had failed conventional therapy showed a 40 percent response-rate to ImmuRAIT-LL2." Immunomedics' lymphoma imaging and therapy agents are under active study at seven medical centers in the United States and Europe.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases. The company currently has one therapeutic and five imaging products in human clinical trials. In addition, the company's colorectal cancer imaging agent, ImmuRAID(TM)-CEA is under review for marketing approval by the United States Food and Drug Administration, as well as by regulatory agencies in Europe and Canada.
 -0- 4/19/93
 /CONTACT: Amy Factor, vice president - finance and administration or Debra Wasser, director of corporate communications, both of Immunomedics, Inc., 201-605-1330, ext. 113/
 (IMMU)


CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:

LR-OS -- NY004 -- 7161 04/19/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 19, 1993
Words:497
Previous Article:LOWEST INTEREST RATES IN 20 YEARS PROMPTS REFINANCE SURGE; COUNTRYWIDE FUNDING OFFERS REFINANCING TIPS
Next Article:INTER-REGIONAL FINANCIAL GROUP REPORTS BEST QUARTER IN COMPANY HISTORY; EARNINGS PER SHARE UP 28 PERCENT ON 12 PERCENT NET REVENUE GAIN
Topics:


Related Articles
IMMUNOMEDICS REPORT NEW RESULTS OF LUNG CANCER AND LYMPHOMA IMAGING AGENTS
IMMUNOMEDICS PRESENTS CANCER THERAPEUTICS AT THE AMERICAN COLLEGE OF NUCLEAR PHYSICIANS IN SAN DIEGO
IMMUNOMEDICS REPORTS FIRST CLINICAL RESULTS OF LYMPHOMA IMAGING AGENT
IMMUNOMEDICS AWARDED ORPHAN DRUG DESIGNATION FOR LYMPHOMA IMAGING AGENT; MAY DETECT LYMPHOMAS IN HIV-INFECTED PATIENTS
IMMUNOMEDICS REPORTS PROMISING LYMPHOMA THERAPY RESULTS; CLINICAL FINDINGS PRESENTED AT ANNUAL NUCLEAR MEDICINE MEETING
IMMUNOMEDICS REPORTS ON LYMPHOMA IMAGING AND THERAPY PROGRESS AT CANCER CONFERENCE
Immunomedics' Investigators Publish Phase III Results Of New Detection Test For Colorectal Cancer
Immunomedics Receives Up-Front Payment of $18MM From Amgen.
Immunomedics Reports Results With Proprietary Diagnostic Imaging Product; Multiple Presentations of Company's LeukoScan(R) (Sulesomab) Product...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters